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Background:  The appearance and disappearance of left ventricular (LV) thrombus following acute myocardial infarction (MI) is unknown 
in the modern era of primary percutaneous coronary intervention (PCI) and its related anti-platelet therapy. We assessed the course of LV 
thrombus formation in the setting of primary PCI comparing contrast-enhanced magnetic resonance imaging (CE-MRI) and routine transthoracic 
echocardiography (TTE) during a 4 month follow period.
Methods: In a prospective cohort study of a total of 194 consecutive patients treated by primary PCI for acute MI, CE-MRI and TTE was obtained at 
baseline and 4 months to assess the presence of mural thrombus formation. On admission, all patients received heparin, aspirin, and clopidogrel.
Results: LV thrombus was visualized in 8.8% (n=17) of the patients on CE-MRI performed at 3.5 +/- 1.3 days after acute MI. TTE diagnosed 4 
of these thrombi, and diagnosed 9 additional patients with LV thrombus formation. At discharge, 8 of 17 patients received additional coumarin 
derivates. Follow-up MRI performed at 4 months showed persistent evidence of thrombus in 1 of 8 patients receiving anti-platelet therapy compared 
to 1 of the 9 patients receiving additional coumarin derivates, but also showed LV thrombi in 12 new patients.During 24-month clinical follow-up, 1 
of the 194 patients without LV thrombus formation had clinical evidence of stroke.
Conclusion: The incidence of LV thrombus in patients with acute MI treated by primary PCI was 8.9% as assessed by MRI. There is a large 
disagreement between routine TTE and CE-MRI in depicting LV thrombi in STEMI patients. In acute MI patients treated by primary PCI and 
concomitant dual anti-platelet therapy, LV thrombi on baseline MRI appear to have a benign course disappearing in 88% of the patients, irrespective 
of warfarin treatment. Whether warfarin with it’s increased bleeding risk should be given to these patients on top of dual anti-platelet therapy, as 
guidelines prescribe, is highly questionable and needs further research.
